SMART-C: Standard vs Simplified Monitoring of Initial HCV Treatment With Glecaprevir/Pibrentasvir

April 10-14, 2019; Vienna, Austria
Simplified monitoring schedule resulted in similar safety and efficacy but was not noninferior to standard monitoring for SVR12 in ITT population.
Format: Microsoft PowerPoint (.ppt)
File Size: 162 KB
Released: April 15, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by:
AbbVie
Gilead Sciences

Related Content

Downloadable slides from CCO expert, Dr. Alain H. Litwin, on integrating HCV and HIV prevention and care strategies into addiction care settings

Alain H. Litwin, MD Released: September 18, 2020

Dr. Stefan Zeuzem discusses new viral hepatitis data reported at the 2020 Digital International Liver Congress, in the CCO Infectious Disease podcast

Stefan Zeuzem, MD Released: September 14, 2020

Expert selections of the most important viral hepatitis data from EASL 2020, including HCV elimination and HCV and HBV treatment, provided by CCO

Stefan Zeuzem, MD Released: September 8, 2020

Latest data and best practice guidance on treating HCV in addiction medicine settings published by Clinical Care Options (CCO)

Andrew Seaman, MD Released: February 24, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue